Treatment patterns and outcomes of patients with relapsed or refractory follicular lymphoma receiving three or more lines of systemic therapy (LEO CReWE): a multicentre cohort studyCarla Casulo, Matthew J. Maurer, Loretta J. Nastoupil et al.|The Lancet Haematology|2022Cited by 65
Outcomes of Relapsed or Refractory Diffuse Large B‐Cell Lymphoma Treated With R‐<scp>GemOx</scp>: A Multicenter Cohort StudySamuel Yamshon, Loretta J. Nastoupil, Jean L. Koff et al.|American Journal of Hematology|2025Cited by 10
Matching-adjusted indirect comparison from the Lymphoma Epidemiology of Outcomes Consortium for Real World Evidence (LEO CReWE) study to a clinical trial of mosunetuzumab in relapsed or refractory follicular lymphomaMatthew J. Maurer, Christopher R. Flowers, Carla Casulo et al.|Haematologica|2023Cited by 8